Cellectar Biosciences, Inc. (CLRB)
D
Pipeline Grade
Financial Position (from SEC Filings)
$8.4M
Cash & Equivalents
$4.9M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$23M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-25 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom | PHASE2 | Active Not Recruiting | 120 |
| NCT07311993 | Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | PHASE1 | Recruiting | 60 |
| NCT05610891 | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG | PHASE1 | Active Not Recruiting | 50 |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | PHASE1 | Active Not Recruiting | 30 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.